Novavax’s regulatory filings are on track, with several already completed. The stock’s valuation remains very attractive. Novavax appears to be the leader in the COVID/flu combo-vaccine race …
https://www.fool.com/investing/2021/11/05/its-time-to-buy-novavax-after-the-biotechs-q3-upda/

